


   
    PharmaCancerRevolution | Prostate Cancer Therapeutics
                     
                
            ðŸŽ¯" Mission Statement"
           
                Prostate cancer remains the second leading cause of cancer death in men. 
                Our platform aggregates cutting-edge pharmacological data on the most promising 
                therapeutic agents targeting castration-resistant prostate cancer (CRPC). 
                We focus on molecules with superior ADME properties, proven clinical efficacy, 
                and novel mechanisms of action.
           
                   "Key Data":
                -FDA-Approved Agets: 5
                - Average Bioavailability: 84%
                - Improvement Rate: 60%
                - Monthly PPS Benefit: 12%

   "Molecular Structures":
   Interactive molecular structures of:
   - Enzalutamide
   - Darolutamide
   - Abiraterone
   - Olaparib
    - 177-Lu-PSMA-617

Hovering over each structure reveals detailed chemical information.      
                    
          -Two other leadinf prostate cacer drugs
   Each structure includes detailed chemical information accessible via interactive visualization.
  

                            
              
                - Enzalutamide -
            
                Enzalutamide (MDV3100)
                
                   ChEMBL ID: CHEMBL1261870
                   Target: AR Antagonist (2nd Gen)
                   Bioavailability: 84%
                    Half-life: 5.8 days
                    IC50: 36 nM (AR binding)
                   Clinical Trial: AFFIRM (NEJM 2012)
                                              
                    Lu-177-PSMA 
                            
                    Lu-177-PSMA-617
                                    
                   Type: Radioligand Therapy
                   Target: PSMA (Prostate-Specific Membrane Antigen)
                    Route: IV infusion
                Half-life: 6.65 days (physical)
                    Response Rate: 46% PSA reduction >50%
                   Clinical Trial: VISION (NEJM 2021)
              
                                   
                    - Olaparib -
           
               Olaparib (Lynparza)
                                   ChEMBL ID: CHEMBL521686
                  Target: PARP1/2 Inhibitor
                   Indication:BRCA1/2 or ATM mutated mCRPC
                    Bioavailability: 60%
                 Half-life: 14.9 hours
                    Clinical Trial: PROfound (NEJM 2020)
                
                   
                       - Abiraterone -
            
                Abiraterone Acetate
                
                   ChEMBL ID: CHEMBL1200920
                    Mechanism: Blocks androgen synthesis
                    Bioavailability: 5% (fasted)
                    Half-life: 12-16 hours
                   Co-administration:Requires prednisone
                

      - ADME Comparison -
       
          
                             Absorption
                   Best:Enzalutamide (84%)
                 Food Effect: Darolutamide (2.25x â†‘)
                  IV Only: Lu-177-PSMA
             
                     Distribution
                  Protein Binding:</strong> 82-99%
                    BBB Penetration: Minimal (Darolutamide) âœ“
                 Vd Range: 110-19,669 L
                
                
                                   Metabolism
                  Primary: CYP3A4 (most)
                  Active Metabolites: Yes (Enzalutamide)
                    Low Interactions: Darolutamide âœ“
                
                     Excretion
                  Renal: Lu-177 (67%)
                    Fecal: Abiraterone (88%)
                    Half-life: 5.8-20 hours
                
        - Comparison Table -
        
                                   Drug
                        Mechanism
                        OS Benefit
                        PFS Benefit
                        Safety Profile
                        Cost/Month
                
                        Darolutamide
                        AR antagonist
                        +18.4 months
                        +22.0 months
                        â­â­â­â­â­
                        $11,000
                   
                       Enzalutamide
                        AR antagonist
                        +4.8 months
                        +8.3 months
                        â­â­â­â­
                        $10,500
                    
                       Lu-177-PSMA
                        Radioligand
                        +4.0 months
                        +5.3 months
                        â­â­â­â­
                        $42,500/cycle
                    
                        Olaparib
                        PARP inhibitor
                        +3.5 months
                        +3.8 months
                        â­â­â­
                        $15,000
                    
                        Abiraterone
                        CYP17 inhibitor
                        +4.6 months
                        +5.6 months
                        â­â­â­
                       $9,000
                    
               
           Data Sources:
                "https://www.ebi.ac.uk/chembl/"reference-link" 
               "https://go.drugbank.com/"reference-link">DrugBank
                "https://pubchem.ncbi.nlm.nih.gov/"reference-link">PubChem
           
           Clinical Trial Data:</strong> ClinicalTrials.gov | NEJM | Lancet Oncology
            "margin-top: 15px; font-size: 0.9em
                Â© 2024 PharmaCancerRevolution | For Educational and Research Purposes Only<br>
                This platform does not provide medical advice. Consult healthcare professionals for treatment decisions.
           
       